entertainment -WSS

entertainment

author：leisure time 2025-09-29 22:51:34 - browse：47254

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Cancer drug shortages' outsize impact on ovarian cancer patients

WSS

CDC recommends RSV monoclonal antibody for infants

2 officers injured in shooting in Orlando, police say

An interview with Robert F. Kennedy Jr. on vaccines

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Liz Cheney makes 1st public comment since Trump's election interference indictments

focus

entertainment

hotspot

In Memoriam: Notable people who died in 2023

Hilary expected to bring catastrophic, life

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Alnylam reports growth in sales of rare disease treatments

After affirmative action ruling, medical educators look to 'holistic review'

Ukraine taking heavy casualties 10 weeks into its counteroffensive

The cancer drug shortage isn’t new — and neither are the solutions

The a glaring gap in research on serious mental illness and primary care

Heart attack and stroke risk calculators need revising

Physicians aren't 'burning out.' They're suffering from moral injury

leisure time

2 officers injured in shooting in Orlando, police say

Trump's false claims about Georgia's 2020 election long debunked

H.R. 3 is the wrong path to lower drug costs

Group behind ProMed defends move to subscription

The pain doctors face in trying to build their families

H.R. 3 is the wrong path to lower drug costs

leisure time

hotspot

explore

Wikipedia